GlassScriptPhysician profile
Dedra Alexander
NPI 1033694955
$4,085.08
in general payments reported to CMS, 2019-2025
23 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $240 · 2023: $281 · 2024: $646 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.63 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,006.31 | 2021-2025 | |
| Alkermes, INC. | $616.32 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $500.46 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $315.94 | 2025 | |
| Axsome Therapeutics, INC. | $259.69 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $217.01 | 2024-2025 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $208.13 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $158.74 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.08 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $124.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $113.85 | 2021 | |
| Collegium Pharmaceutical, INC. | $81.61 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $58.31 | 2025 | Qelbree |
| Lilly USA, LLC | $44.37 | 2021 | |
| Indivior INC. | $40.40 | 2025 | Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.76 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $34.18 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $32.36 | 2023 | Cequa |
| Gilead Sciences, INC. | $23.75 | 2025 | Epclusa |
| Biohaven Pharmaceutical Holding Company LTD. | $16.69 | 2022 | |
| Sage Therapeutics, LLC | $16.12 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $11.88 | 2022 | |
| Corium, LLC | $7.35 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dedra Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.